Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome

Background : Overactive Bladder Syndrome(OAB) is not an uncommon problem. Although exact incidence of this disease in our country is not known but a significant number of people suffering from this disease seek treatment at the Urology department of different hospitals. At present two common antimuscarinic drug Solifenacin Succinate and Tolterodine are available in our country for the treatment of OAB.Objective : To compare the efficacy of Solifenacin Succinate and Tolterodine to treat OAB.Methodology : This hospital based randomized control trial was conducted in the Department of Urology, Dhaka Medical College Hospital, Dhaka and a private hospital from January 2009 to December 2010 to compare the efficacy of two new generation antimuscarinics, Solifenacin succinate and Tolterodine at their recommended doses for the treatment of OAB.Results : After 3 months of treatment it has clearly shown that Solifenacin is more effective in reducing OAB symptoms compared with extended release preparation of Tolterodine. This include statistically significant reduction in episodes of frequency, urgency, urge incontinence, nocturia and significant improvement of voided volume.Northern International Medical College Journal Vol.8(2) January 2017: 231-234

Download Full-text

POD-01.08: Persistence with Solifenacin and Tolterodine Extended Release in Patients with Overactive Bladder Syndrome, According To Patient Age

Urology ◽

10.1016/j.urology.2009.07.1213 ◽

2009 ◽

Vol 74 (4) ◽

pp. S3-S4

Author(s):

A. Fahey ◽

E. Siddiqui ◽

G. Compion

Keyword(s):

Overactive Bladder ◽

Extended Release ◽

Overactive Bladder Syndrome ◽

Patient Age ◽

Patient Âgé

Download Full-text

Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR trial. Eur Urol 2005;48:464–70

European Urology ◽

10.1016/j.eururo.2005.09.013 ◽

2006 ◽

Vol 49 (1) ◽

pp. 187-188 ◽

Cited By ~ 2

Author(s):

Udo Jonas ◽

Raymond R. Rackley

Keyword(s):

Overactive Bladder ◽

Extended Release ◽

Overactive Bladder Syndrome ◽

Solifenacin Succinate ◽

Star Trial

Download Full-text

Development, optimization and pharmacokinetic evaluation of biphasic extended-release osmotic drug delivery system of trospium chloride for promising application in treatment of overactive bladder

Future Journal of Pharmaceutical Sciences ◽

10.1186/s43094-021-00311-6 ◽

2021 ◽

Vol 7 (1) ◽

Author(s):

Ramakanth Gundu ◽

Sanjay Pekamwar ◽

Santosh Shelke ◽

Deepak Kulkarni ◽

Santosh Shep

Keyword(s):

Drug Delivery ◽

Drug Release ◽

Overactive Bladder ◽

Drug Delivery System ◽

Delivery System ◽

Extended Release ◽

Pharmacokinetic Analysis ◽

Trospium Chloride ◽

Release System ◽

Promising Application

Abstract Background The research was aimed with an approach to formulate biphasic extended-release system of trospium chloride resulting in controlled release of drug up to 24 h with prospects of better control on urinary frequency, efficacy, tolerability, and improved patient compliance. The push–pull osmotic pump (PPOP) bi-layered tablet of trospium chloride (60 mg) was developed with the use of immediate-release polymers in the pull layer (30 mg drug) and polyethylene oxide in the push layer (remaining 30 mg drug). The tablet was formulated by compression after non-aqueous granulation, seal coating, and semipermeable coating. The tablet prepared was laser drilled to create an orifice for drug release. Results Comparative in vitro dissolution and in vivo pharmacokinetic analysis of available marketed formulations demonstrated the complete drug release within 16–18 h; hence the developed biphasic extended-release system has its great importance as it provides zero-order release up to 24 h. Conclusions The developed biphasic extended-release drug delivery system of trospium chloride provides the drug release for 24 h with effective plasma concentration in comparison with the available marketed formulation. Extended release of drug from the developed formulation provides scope for its promising application in the treatment of overactive bladder (OAB).

Download Full-text